Linker Information
General Information of This Linker
| Linker ID |
LIN0JCABZ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
ADC 2-A linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
ADC2-A [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
83.10%
|
Low HER2 expression (HER2 +) | ||
| Method Description |
Seeding cells (Capan-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
88.40%
|
Moderate HER2 expression (HER2 ++) | ||
| Method Description |
Seeding cells (JIMT-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max inhibition rate (MIR) |
95.30%
|
High HER2 expression (HER2+++) | ||
| Method Description |
The in vitro potency of ADC was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.03 nM
|
High HER2 expression (HER2+++) | ||
| Method Description |
The in vitro potency of ADC was measured in a panel of cancer cell lines usingthe CellTiter-Glo Luminescent Viability Assay.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.17 nM
|
Moderate HER2 expression (HER2 ++) | ||
| Method Description |
Seeding cells (JIMT-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
3.94 nM
|
Low HER2 expression (HER2 +) | ||
| Method Description |
Seeding cells (Capan-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.